The scope of the obesity epidemic in the United States has been greatly underestimated, according to a study published Apr. 2 in the open access journal PLoS ONE. Researchers found that the Body Mass Index (BMI) substantially under-diagnoses obesity when compared to the Dual Energy X-ray Absorptiometry (DXA) scan, a direct simultaneous measure of body fat, muscle mass, and bone density.
The disparity is particularly significant for women of advancing age, those with high blood leptin levels, and the normal weight obese.
The study found that as many as 39 percent of Americans who are classified as overweight based on BMI are actually obese as measured by DXA.
"The BMI is an insensitive measure of obesity, prone to under-diagnosis," said Eric Braverman, M.D., one of the authors of the study, "while direct fat measurements are superior because they show distribution of body fat."
Co-authors Braverman and Nirav Shah, M.D., M.P.H., recognize the convenience, safety, and low cost of the BMI, yet agree that it is an outdated mathematical equation that needs to evolve in order to correctly evaluate body fat.
"These estimates are fundamental to U.S. policy addressing the epidemic of obesity and are central to designing interventions aimed at curbing its growth," the authors say, "yet the [current policies] may be flawed because they are based on the BMI."
The authors also found that levels of leptin, a hormone protein, are strongly correlated to body fat. They suggest that, in the absence of DXA, leptin levels may be used in conjunction with BMI to provide a more accurate measure of adiposity, and provide a leptin-adjusted BMI table to do so. They also note that the American Society of Bariatric Physicians use both BMI and DXA as criteria for interventions, which "may be a reasonable transition in public health policy."
Eric R. Braverman, M.D. and Nirav Shah, M.D. * will be available at Rockefeller Research Laboratory Auditorium April 4th, 2012 to discuss the findings further. Nora Volkow, M.D. the director of the National Institute on Drug Abuse will also be speaking about the role of the brain in controlling leptin levels.
RRL Auditorium
430 East 67th Street (Between 1st and York Avenue)
New York, NY 10065
Nirav Shah, M.D., M.P.H is the current New York State Commissioner of Health. At the time the research was completed he was Assistant Professor in the Department of Medicine at New York University School of Medicine. *seminar attendance not confirmed
Eric Braverman, M.D. is the Founder and President of PATH Foundation NY, a non-profit devoted to establishing how the brain functions and developing practical diagnostic and treatment methods that improve well-being and increase longevity.
Disclaimer: This press release refers to upcoming articles in PLoS ONE. The releases have been provided by the article authors and/or journal staff. Any opinions expressed in these are the personal views of the contributors, and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.
About PLoS ONE
PLoS ONE is the first journal of primary research from all areas of science to employ a combination of peer review and post-publication rating and commenting, to maximize the impact of every report it publishes. PLoS ONE is published by the Public Library of Science (PLoS), the open-access publisher whose goal is to make the world's scientific and medical literature a public resource.
All works published in PLoS ONE are Open Access. Everything is immediately available—to read, download, redistribute, include in databases and otherwise use—without cost to anyone, anywhere, subject only to the condition that the original authors and source are properly attributed. For more information about PLoS ONE relevant to journalists, bloggers and press officers, including details of our press release process and our embargo policy, see the everyONE blog at http://everyone.plos.org/media.
Journal
PLoS ONE